Autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 is a potential serological marker for renal cell carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 5, 2011, Pages 789-794

  Tanaka, Toshiaki ^a   Kitamura, Hiroshi ^a   Torigoe, Toshihiko ^a   Hirohashi, Yoshihiko ^a   Sato, Eiji ^a   Masumori, Naoya ^a   Sato, Noriyuki ^a   Tsukamoto, Taiji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; PHD3 protein; Renal cell carcinoma; Tumor marker

Indexed keywords

HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE 3; HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE 3 ANTIBODY; OXYGENASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; CARCINOMA, RENAL CELL; DIOXYGENASES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RNA, MESSENGER; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 79955703685     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0940-6     Document Type: Article

References (20)

1. Appelhoff RJ, Tian YM, Raval RR, Turley H, Harris AL, Pugh CW, Ratcliffe PJ, Gleadle JM (2004) Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 279:38458-38465 (Pubitemid 39295997)
2. Barua A, Bradaric MJ, Kebede T, Espionosa S, Edassery SL, Bitterman P, Rotmensch J, Luborsky JL (2007) Anti-tumor and anti-ovarian autoantibodies in women with ovarian cancer. Am J Reprod Immunol 57:243-249 (Pubitemid 46394836)
3. Campbell SC, Novick AC, Bukowski RM (2007) Renal tumors. In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds) Campbell-Walsh urology, vol 2, 9th edn. Saunders Elsevier, Philadelphia, pp 1567-1637
4. Cioffi CL, Liu XQ, Kosinski PA, Garay M, Bowen BP (2003) Differential regulation of HIF-1α prolyl-4-hydroxylase genes by hypoxia in human cardiovascular cells. Biochem Biophys Res Commun 303:947-953 (Pubitemid 36384947)
5. Hirsilä M, Koivunen P, Günzler V, Kivirikko KI, Myllyharju J (2003) Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 278:30772-30780 (Pubitemid 36994584)
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
7. Kitamura H, Honma I, Torigoe T, Hariu H, Asanuma H, Hirohashi Y, Sato E, Sato N, Tsukamoto T (2007) Expression of livin in renal cell carcinoma and detection of anti-livin autoantibody in patients. Urology 70:38-42 (Pubitemid 47081114)
8. Larsson A, Ronquist G, Wülfing C, Eltze E, Bettendorf O, Carlsson L, Nilsson BO, Semjonow A (2006) Antiproteasome antibodies: possible serum markers for prostate cancer metastasizing liability. Urol Oncol 24:195-200
9. Maynard MA, Ohh M (2007) The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 64:2170-2180 (Pubitemid 350103108)
10. Nilsson BO, Carlsson L, Larsson A, Ronquist G (2001) Autoantibodies to prostasomes as new markers for prostate cancer. Upsala J Med Sci 106:43-49
11. Sato E, Torigoe T, Hirohashi Y, Kitamura H, Tanaka T, Honma I, Asanuma H, Harada K, Takasu H, Masumori N, Ito N, Hasegawa T, Tsukamoto T, Sato N (2008) Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma. Clin Cancer Res 14:6916-6923
12. Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, Kobayashi S, Ochiai T (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677-1683
13. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, Hayashi H, Takeda A, Ochiai T (2002) Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 132:41-47 (Pubitemid 34787820)
14. Sobin LH, Wittekind Ch (eds) (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York
15. Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H (2004) Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. J Urol 171:182-186 (Pubitemid 37549119)
16. Takeda A, Shimada H, Nakajima K, Yoshimura S, Suzuki T, Asano T, Ochiai T, Isono K (2001a) Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection. Int J Clin Oncol 6:45-49 (Pubitemid 32230363)
17. Takeda A, Shimada H, Nakajima K, Imaseki H, Suzuki T, Asano T, Ochiai T, Isono K (2001b) Monitoring of p53 autoantibodies after resection of colorectal cancer: Relationship to operative curability. Eur J Surg 167:50-53 (Pubitemid 32066221)
18. Tan EM, Zhang J (2008) Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 222:328-340 (Pubitemid 351430373)
19. Yagihashi A, Asanuma K, Tsuji N, Torigoe T, Sato N, Hirata K, Watanabe N (2003) Detection of anti-livin antibody in gastrointestinal cancer patients. Clin Chem 49:1206-1208 (Pubitemid 36751117)
20. Zhong L, Ge K, Zu JC, Zhao LH, Shen WK, Wang JF, Zhang XG, Gao X, Hu W, Yen Y, Kernstine KH (2008) Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res. doi:10.1186/bcr2091